Related Experiment Videos
Intravenous pamidronate treatment in osteogenesis imperfecta
1Istituto di Clinica Pediatrica, Carattere Scientifico Burlo Garofolo, Trieste, Italy.
Insights
Pamidronate treatment significantly reduced fractures and improved quality of life in children with osteogenesis imperfecta. Bone density increased, and linear growth continued with no adverse effects observed.
Area of Science:
- Pediatric Endocrinology
- Pediatric Orthopedics
- Pharmacology
Background:
- Osteogenesis imperfecta (OI) is a genetic disorder characterized by brittle bones, leading to frequent fractures and impaired growth.
- Severe osteopenia and recurrent fractures pose significant challenges in managing pediatric OI cases.
- Bisphosphonates, such as pamidronate, are investigated for their potential to improve bone health in OI.
Observation:
- Three children diagnosed with severe osteogenesis imperfecta and recurrent fractures were enrolled in the study.
- Patients received cyclic infusions of aminohydroxypropylidene bisphosphonate (pamidronate) over a treatment period of 22 to 29 months.
- Clinical assessments focused on fracture frequency, bone mineral density, linear growth, and overall quality of life.
Findings:
- Cyclic pamidronate therapy resulted in a marked reduction in new fracture episodes among the pediatric patients.
- Significant improvements in bone mineral density were observed in two of the three treated children.
- Linear growth was maintained along the initial percentile, and patients reported a notable enhancement in their quality of life.
- No significant adverse effects were reported during the treatment period, suggesting good tolerability.
Implications:
- Pamidronate demonstrates therapeutic potential for managing severe osteogenesis imperfecta in children, improving skeletal integrity and daily functioning.
- The findings support the use of bisphosphonate therapy as a viable treatment option for pediatric OI, warranting further investigation.
- Long-term studies are recommended to fully evaluate the sustained efficacy and safety profile of pamidronate in this patient population.
Abstract:
Three children with osteogenesis imperfecta, severe osteopenia, and repeated fractures were treated with cyclic infusions of aminohydroxypropylidene bisphosphonate (pamidronate) for a period ranging from 22 to 29 months. A clear clinical response was shown, with a striking reduction of new fracture episodes and a marked improvement in the quality of the patients' lives. Bone mineral density increased significantly in two patients, and linear growth continued along the percentile at the start of treatment. There were no adverse effects of note during treatment, and further studies are warranted.